Health Reading List | November 27, 2015 |
Startup Highlight: Kuveda
There are a number of companies looking at personalized medicine and genomics specifically for the purpose of cancer care. One of the main differences with Kuveda, is they have no dog in the fight for the eventual course of action for the patient (vs. other platforms that also have therapeutics that they are pushing). It will be amazing to see how the industry evolves, and how companies like Kuveda differentiate as more "big data" players enter the cancer market around personalized medicine.
As always, if you come across news, announcements, videos, or podcasts that you think everyone else would benefit from, e-mail me at scott.munro@startupdigestmail.com or tweet @R_Scott_Munro. | Voting for GSB Now Open!  Choose the Winner of Global Startup Battle! Voting is now open for GSB 2015 and ends Dec 4th. Check out the videos and vote for your favorite: go.up.co/vote. | | "In this interview, Dr. Eric Schadt, the founding director of the Icahn Institute for Genomics and Multiscale Biology at New York's Mount Sinai Health System, tells McKinsey's Sastry Chilukuri how data-driven approaches to research can help patients, in what ways technology has the potential to transform medicine and the healthcare system, and how the Icahn Institute is building its talent base. An edited transcript of Schadt's remarks follows." | | I've harped on this for a while... but all these wearables that are out there can be tracking data that does not have a clear clinical use case... this article explores that thought specifically around fitness data we can collect as health consumers. | | Rice University isn't waiting for Theranos to release data around finger prick tests, they went ahead and did a study on their own. The results aren't great and found that test results can vary significantly drop to drop. | | A deep dive into the CMS data around meaningful use for EHRs shows, "top vendors have solidified market dominance in inpatient and outpatient spheres." | | A piece that does not take a light stance on the Pfizer-Allergan "inversion" merger. | | "In this episode of Disruptive, Wyss Core Faculty Member Dave Mooney discusses programmable nanomaterials approaches to fighting disease. Mooney explains how a cancer vaccine, developed by his team and currently in a clinical trial at the Dana-Farber Cancer Institute, can train one's own immune system to target specific cancer cells. He also describes the development of novel hydrogels that find application in drug delivery systems and tissue regeneration." | | | You are receiving this email because you believe that the best startup articles and videos are made by active members of the startup community. Startup Digest, © 2009-2015 by Techstars Central LLC. All rights reserved. Startup Digest is a registered trademark of Techstars Central, LLC. Privacy Policy. | | |
No comments:
Post a Comment